What you need to know about the CBO rebate rule score
By Tom Wilbur | May 23, 2019
Earlier this year, the Department of Health & Human Services (HHS) Office of Inspector General (OIG) released a proposed rule that takes aim at today’s complex system of list prices and rebates in...
Read More
World Trade Month: How we can expand world-class pro-innovation standards
By Douglas Petersen | May 22, 2019
May is World Trade Month—a celebration of the industries that import and export goods and services around the world. The month offers a good opportunity to examine the significance of...
Read More
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
By Tom Wilbur | May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...
Read More
Fresh data show, yet again, 340B is growing while charity care dwindles at many 340B hospitals
By Nicole Longo | May 16, 2019
There has been broad acknowledgement in Congress and by the Administration, as well as by patient groups and some hospitals, that the 340B program is not working as Congress intended. Yet little...
Read More
Clinical Trials Awareness Week: Celebrating innovation in clinical research
By Richard Moscicki, M.D. | May 15, 2019
This week is Clinical Trials Awareness Week — an annual event to recognize the important role clinical trials play in helping develop safe and effective medicines.
Read More
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
By Guest Contributor | May 15, 2019
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Leah L. Zullig, PhD.
Read More
New study finds hospitals continue to push patients to costlier outpatient settings
By Holly Campbell | May 13, 2019
A new study from the Health Care Cost Institute found that, for commercially insured patients, almost 50 percent of medicines administered by physicians, including treatments for diseases like...
Read More
New Report: Advanced manufacturing powering innovative biopharmaceuticals
By Tim McClung | May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...
Read More
Today, IQVIA released its Medicine Use and Spending in the U.S. – A Review of 2018 and Outlook to 2023 report – highlighting the drivers behind medicine price and spending trends, patient...
Read More
Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”
By Holly Campbell | May 9, 2019
Reinforcing our industry’s commitment to providing patients with more transparency about medicine costs, yesterday, our member companies announced the launch of the Medicine Assistance Tool, or MAT
Read More
Guest Post: The importance of women, diversity and inclusion in STEM
By Guest Contributor | May 8, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
By Tiffany Haverly | May 8, 2019
PhRMA is committed to working with lawmakers to ensure patients can access and afford their medicines, but importation schemes that put patient safety at risk are the wrong approach. In a recent...
Read More
Event tomorrow: Improving access and affordability for America’s seniors
By Andrew Powaleny | May 7, 2019
Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...
Read More
Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices
By Nicole Longo | May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...
Read More
Clinical trials impact state economies
By John Corea | May 3, 2019
A new report from TEConomy Partners, supported by PhRMA, provides estimates of industry-sponsored clinical trial activity in each of the 50 states, including the number of trials active, the...
Read More
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
By Tom Wilbur | May 2, 2019
Strong patent protections are fundamental to the creation of new treatments and cures that extend and improve patients’ lives. In recent years, critics of the biopharmaceutical industry have...
Read More
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
